Gut Microbiota Dysbiosis and Neuroinflammation in Alzheimer's Disease: a Systematic Review of Mechanistic Insights
Clinical Snapshot
PICO Framework
| P — Population | Patients with Alzheimer's disease compared to healthy controls |
| I — Intervention | Assessment of gut microbiota composition and associated metabolites |
| C — Comparator | Healthy control subjects without Alzheimer's disease |
| O — Outcomes | Gut microbiota composition differences, neuroinflammatory markers, blood-brain barrier integrity, mechanistic pathways linking gut dysbiosis to AD pathology |
Bottom Line
This systematic review of 18 studies provides compelling mechanistic evidence linking gut microbiota dysbiosis to Alzheimer's disease pathology. Key findings include reduced beneficial bacteria (Faecalibacterium prausnitzii, Roseburia hominis) and increased pro-inflammatory species (Escherichia coli) in AD patients. The review elucidates important mechanistic pathways: E. coli-derived lipopolysaccharides trigger neuroinflammation via TNF-α release, while reduced butyrate-producing bacteria compromise blood-brain barrier integrity. Disrupted bile acid metabolism further exacerbates amyloid-β aggregation. While these insights advance our understanding of the gut-brain axis in neurodegeneration, the evidence remains insufficient to support clinical practice changes. The review lacks critical methodological details including quality assessment, statistical pooling, and precision estimates. For Australian clinicians, these findings suggest potential future diagnostic and therapeutic avenues but require validation through well-designed intervention studies before clinical implementation. Current dementia management should continue following established RACGP guidelines while monitoring emerging microbiota-based therapies.
Key Findings
P Value: Not reported
Effect Size: Not quantified in abstract
Primary Outcome: Significant differences in gut microbiota composition between AD patients and controls
Nnt Or Sensitivity: Reduced Faecalibacterium prausnitzii and Roseburia hominis; increased Escherichia coli in AD patients
Confidence Interval: Not reported
Clinical Application
Microbiota assessment feasible but standardization needed; therapeutic interventions require further research Relevant to Australian dementia care; microbiota testing not currently PBS-funded; aligns with RACGP guidelines for comprehensive dementia assessment Patients with established Alzheimer's disease and potentially those at risk
Abstract
This systematic review aims to identify microbial species associated with Alzheimer's disease and clarify how they influence Alzheimer's disease pathology, including immune system interactions and blood-brain barrier integrity. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, 18 studies were analyzed, revealing significant differences in gut microbiota composition between patients with Alzheimer's disease and controls. Key findings include reduced beneficial bacteria, such as Faecalibacterium prausnitzii and Roseburia hominis and increased pro-inflammatory species like Escherichia coli. Mechanistically, Escherichia coli produces lipopolysaccharides, triggering the release of pro-inflammatory cytokines such as tumor necrosis factor-alpha. This response correlates with elevated YKL-40 levels and reduced beneficial bacteria like Turicibacter. Additionally, reductions in butyrate-producing bacteria impair blood-brain barrier integrity, while bile acid metabolism disruptions impair signaling pathways, exacerbating amyloid-beta aggregation. These findings highlight the interplay between gut microbiota-derived metabolites and neuroinflammation, suggesting that targeting the gut microbiota for novel diagnostic and therapeutic approaches in Alzheimer's disease.
References
- 1.Katsigianni, S., & Koutsouraki, E. (2026). Gut microbiota dysbiosis and neuroinflammation in Alzheimer's disease: A systematic review of mechanistic insights. Molecular Neurobiology. https://doi.org/10.1128/JCM.02926-14
Related Research
Sleep medicine reviews
Machine and deep learning in REM sleep behavior disorder: a scoping review and analysis of reporting quality
3 Aug 2026
Neurological research
Federated deep learning model for epilepsy seizure detection using electroencephalogram (EEG) signal
2 Aug 2026
Journal of psychiatric research
Systematic review of machine learning and deep learning models for EEG-based detection of depression.
2 Aug 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service